Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.

[1]  A. Moreira,et al.  Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Rehan Akbani,et al.  Integrated Molecular Characterization of Uterine Carcinosarcoma. , 2017, Cancer cell.

[3]  S. Mane,et al.  Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition , 2016, Proceedings of the National Academy of Sciences.

[4]  D. Huntsman,et al.  In‐depth molecular profiling of the biphasic components of uterine carcinosarcomas , 2015, The journal of pathology. Clinical research.

[5]  Jae-Weon Kim,et al.  Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma , 2014, International Journal of Gynecologic Cancer.

[6]  Ethan Cerami,et al.  Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes , 2014, Nature Communications.

[7]  A. Neugut,et al.  Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome. , 2013, Gynecologic oncology.

[8]  Ning Leng,et al.  EBSeq: an empirical Bayes hierarchical model for inference in RNA-seq experiments , 2013, Bioinform..

[9]  Paul Scheet,et al.  Haplotype-based profiling of subtle allelic imbalance with SNP arrays , 2013, Genome research.

[10]  D. Gaffney,et al.  Does the FIGO 2009 Endometrial Cancer Staging System More Accurately Correlate With Clinical Outcome in Different Histologies? Revised Staging, Endometrial Cancer, Histology , 2011, International Journal of Gynecologic Cancer.

[11]  R. Kanthan,et al.  Uterine Carcinosarcomas (Malignant Mixed Müllerian Tumours): A Review with Special Emphasis on the Controversies in Management , 2011, Obstetrics and gynecology international.

[12]  Jason D. Wright,et al.  Uterine carcinosarcoma , 2011, Current opinion in oncology.

[13]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[14]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[15]  G. Abecasis,et al.  MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes , 2010, Genetic epidemiology.

[16]  W. Cliby,et al.  The impact of multi-modal therapy on survival for uterine carcinosarcomas. , 2010, Gynecologic oncology.

[17]  Rochelle L. Garcia,et al.  Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[18]  K. Donhuijsen,et al.  Overrepresentation of 8q in carcinosarcomas and endometrial adenocarcinomas. , 2004, American journal of clinical pathology.

[19]  T. Motoyama,et al.  Carcinosarcomas (Malignant Mullerian Mixed Tumors) of the Uterus and Ovary: A Genetic Study With Special Reference to Histogenesis , 2003, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[20]  W. McCluggage,et al.  Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas , 2002, International Journal of Gynecologic Cancer.

[21]  G. Fleuren,et al.  Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed Müllerian tumours , 1997, The Journal of pathology.

[22]  K. Shroyer,et al.  Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. , 1997, Cancer research.

[23]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[24]  R. Hruban,et al.  Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. , 2000, Cancer research.